The Antibody Society is an international, non-profit trade association serving individuals and organizations involved in antibody-related research and development. We research and analyze data on targeted therapeutics developed by the biopharmaceutical industry, and distribute our results and commentary via the Society’s website, presentations and publications. The Society hosts educational webinars and Symposia, and serves as the home for the Adaptive Immune Receptor Repertoire (AIRR) Community, which focuses on the generation, use, sharing and standardization of next-generation sequencing of antibodies and T cell receptors. In addition, we engage with international agencies on matters of importance to the antibody community.

Our members serve as the Scientific Advisors for the Antibody Engineering & Therapeutics conferences. The scientific programs for the meetings are designed by our Meetings Committee.

The Antibody Society Meeting Committee Members

• Jonathan Sockolosky, Ph.D., Senior Director, CSO Partner Team, Curie.Bio (Co-chair)
• James A. Ernst, Ph.D., Vice President, Development Sciences; Head of Protein Sciences & Technology, Xencor (Co-chair)
• Pam Borghardt. AIRR Community Executive Director
• Jan Terje Andersen, Ph.D., Professor, University of Oslo and Group Leader Oslo University Hospital, Norway
• Jamie Spangler, Ph.D., Assistant Professor, Biomedical Engineering and Chemical & Biomolecular Engineering, Johns Hopkins University
• Stephen Beers, Ph.D., Professor of Immunology and Immunotherapy, Antibody and Vaccine Group, Centre for Cancer Immunology, University of Southampton, United Kingdom
• Mitchell Ho, Ph.D., Senior Investigator, Laboratory of Molecular Biology, NIH NCI

Antibody Engineering & Therapeutics Event Advisors

• Katherine Harris, Ph.D., Chief Development Officer, Rondo Therapeutics
• Janine Schuurman, Ph.D., Biotech Consultant, Lust for Life Science
• Sally Ward, Ph.D., Professor and Director, University of Southampton, United Kingdom
• Paul W.H.I. Parren, Ph.D., Professor, Department of Immunohematology and Blood Transfusion, Leiden University Medical Center and EVP and Founder and CSO, Gyes BV
• Kerry A. Chester, Ph.D., Professor of Molecular Medicine, UCL Cancer Institute, University College London, United Kingdom
• Andrew Bradbury, M.D., Ph.D., Chief Scientific Officer, Specifica
• Gregory Adams, Ph.D., Chief Scientific Officer, Elucida Oncology
• James Larrick, M.D., Ph.D., Managing Director and Chief Medical Officer, Panorama Research Institute
• K. Dane Wittrup, Ph.D., C.P. Dubbs Professor of Chemical Engineering and Biological Engineering, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology
• Jennifer Cochran, Ph.D., Professor and Department Chair of Bioengineering, Stanford University
• Jean-Philippe Bürckert, Ph.D., Executive Director, Voredos SRL